• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

Johns Hopkins Vasculitis Center

Show Search
Hide Search
  • About Our Center
    • Appointments and Directions
    • Meet Our Team
    • Support Our Center
  • What is Vasculitis?
    • Types of Vasculitis
    • Causes of Vasculitis
    • Symptoms of Vasculitis
    • Diagnosing Vasculitis
  • Vasculitis Treatments
    • Prednisone
    • Avacopan (Tavneos®)
    • Apremilast (Otezla®)
    • Azathioprine
    • Colchicine
    • Cyclophosphamide (Cytoxan)
    • Dapsone
    • Supplemental Immunoglobulin (IVIG/SCIG)
    • Leflunomide
    • Mepolizumab (Nucala®)
    • Methotrexate (MTX)
    • Mycophenolate
    • Rituximab
    • Sarilumab (Kevzara®)
    • TNF Inhibitors
    • Tocilizumab (Actemra®)
  • Vasculitis Research
  • Resources
Home / Vasculitis Treatments / Methotrexate (MTX)

Methotrexate (MTX)

What is methotrexate?

Methotrexate is an oral or injected drug used in the treatment of nearly every form of vasculitis. In fact, methotrexate is used in the treatment of most diseases seen by rheumatologists.

How does methotrexate work?

Methotrexate works by interfering with the replication of immune cells.

How is methotrexate given?

Methotrexate is always given once per week. It can be administered two ways: as pills taken by mouth, or as liquid that is injected subcutaneously. Patients who take methotrexate always need to take 1 mg folic acid by mouth every day to prevent side effects.

Side effects:

The side effects of methotrexate can be reduced by taking folic acid. Typical side effects can include hair thinning, oral ulcers, fatigue, nausea or diarrhea. We pay particular attention to liver function tests, renal function, and blood counts while using methotrexate. Patients taking methotrexate should not drink alcohol while using this medication.

All immunosuppressants require regular monitoring in the form of blood tests, in-person assessments, and prompt attention to any signs or symptoms of infection.

Receive the Latest News from Johns Hopkins Rheumatology

Receive the Latest News from Johns Hopkins Rheumatology

Join our mailing list to receive the latest news and updates from Johns Hopkins Rheumatology.

Interested In

You have Successfully Subscribed!

Use of this Site

All information contained within the Johns Hopkins Vasculitis website is intended for educational purposes only. Physicians and other health care professionals are encouraged to consult other sources and confirm the information contained within this site. Consumers should never disregard medical advice or delay in seeking it because of something they may have read on this website.

Primary Sidebar

  • Prednisone
  • Avacopan (Tavneos®)
  • Apremilast (Otezla®)
  • Azathioprine
  • Colchicine
  • Cyclophosphamide (Cytoxan)
  • Dapsone
  • Supplemental Immunoglobulin (IVIG/SCIG)
  • Leflunomide
  • Mepolizumab (Nucala®)
  • Methotrexate (MTX)
  • Mycophenolate
  • Rituximab
  • Sarilumab (Kevzara®)
  • TNF Inhibitors
  • Tocilizumab (Actemra®)

Footer

Johns Hopkins Rheumatology

  • Johns Hopkins Rheumatology
  • Johns Hopkins Arthritis Center
  • Johns Hopkins Lupus Center
  • Johns Hopkins Lyme Disease Research Center
  • Johns Hopkins Myositis Center
  • Johns Hopkins Scleroderma Center
  • Johns Hopkins Sjögren’s Syndrome Center

Connect With Us

  • Facebook
  • Twitter
  • YouTube
U.S. News and World Report Rankings Badge

Johns Hopkins Medicine

© 2025 Johns Hopkins Vasculitis Center
Patient Privacy